Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315487 | 0.93 | GSK3B (0.45) | GSK3BPIK3CAPIK3C3CYP2D6CYP1A2 | |
| SCHEMBL316247 | 0.93 | GSK3B (0.48) | GSK3BPIK3CAPIK3C3CYP2D6CYP1A2 | |
| Hydrochloric Acid SCHEMBL316027 | 0.92 | GSK3B (0.47) | GSK3BPIK3CAPIK3C3CYP2D6CYP1A2 | |
| SCHEMBL316032 | 0.91 | GSK3B (0.44) | GSK3BPIK3CAPIK3C3CYP2D6CYP1A2 | |
| SCHEMBL316432 | 0.91 | PIK3CA (0.44) | GSK3BPIK3CAPIK3C3CYP2D6CYP1A2 | |
| SCHEMBL315353 | 0.91 | GSK3B (0.44) | GSK3BPIK3CAPIK3C3CYP2D6CYP1A2 | |
| SCHEMBL315660 | 0.90 | GSK3B (0.42) | GSK3BPIK3CAPIK3C3CYP2D6CYP1A2 | |
| SCHEMBL6445946 | 0.89 | PIK3CA (0.42) | GSK3BPIK3CAPIK3C3CYP2D6CYP1A2 | |
| SCHEMBL315672 | 0.87 | SLC18A3 (0.43) | GSK3BPIK3CAPIK3C3CYP2D6CYP1A2 | |
| SCHEMBL315236 | 0.85 | GSK3B (0.43) | GSK3BPIK3CACYP2D6CYP1A2PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093256-B2 | Use of 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2012-01-10 | — | — | US | claimed |
| EP-1608654-B1 | 8-SUBSTITUTED-6, 7, 8,9-TETRAHY9DROPYRIMIDO (1,2- a) PYRIMIDIN-4-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2009-12-23 | — | — | EP | claimed |
| US-20080021046-A1 | USE OF 8-SUBSTITUTED-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | US | claimed |
| US-7247638-B2 | 8-Substituted-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one derivatives. | SANOFI-AVENTIS (FR) | 2007-07-24 | — | — | US | claimed |
| US-20060035885-A1 | 8-Substituted-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2006-02-16 | — | — | US | claimed |
| EP-1460075-A1 | Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives | SANOFI-SYNTHELABO (FR) | 2004-09-22 | — | — | EP | claimed |
| US-8093256-B2 | Use of 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2012-01-10 | — | — | US | disclosed |
| EP-1608654-B1 | 8-SUBSTITUTED-6, 7, 8,9-TETRAHY9DROPYRIMIDO (1,2- a) PYRIMIDIN-4-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2009-12-23 | — | — | EP | disclosed |
| US-20080021046-A1 | USE OF 8-SUBSTITUTED-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | US | disclosed |
| US-7247638-B2 | 8-Substituted-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one derivatives. | SANOFI-AVENTIS (FR) | 2007-07-24 | — | — | US | disclosed |
| US-20060035885-A1 | 8-Substituted-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2006-02-16 | — | — | US | disclosed |
| EP-1608654-A2 | 8-SUBSTITUTED-6, 7, 8,9-TETRAHY9DROPYRIMIDO (1,2- a) PYRIMIDIN-4-ONE DERIVATIVES | Sanofi-Aventis (FR) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004082577-A2 | 8-SUBSTITUTED-6, 7, 8, 9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2004-09-30 | — | — | WO | disclosed |
| EP-1460075-A1 | Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives | SANOFI-SYNTHELABO (FR) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035885-A1 | 8-Substituted-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one derivatives | GSK3A, PSEN1, GSK3B | GSK3B 3/4885PIK3CA 175/4885PIK3C3 2653/4885 |
| US-20080021046-A1 | USE OF 8-SUBSTITUTED-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | GSK3B 1/4885PIK3CA 81/4885PIK3C3 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.